TICKERNERD
Menu
TPSTTPSTHealthcare · Biotechnology

TPST Stock Forecast: Tempest Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$0.97

The 1 Wall Street analysts covering Tempest Therapeutics, Inc. hold a median 12-month price target of $11 — +1036.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$16.0M
Ticker Nerd rank
37 / 100
Median analyst target
$11
Analysts covering
1
Revenue$0.0
Operating income−$5.3M
Net income−$5.2M
Free cash flow−$2.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

TPST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tempest Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
90
Accruals
90
Growth
87
Issuance
53
Value
28
Revisions
25
Momentum
16
Quality
15
Volatility
11

Size (90): Smaller than most of the companies we track.

Volatility (11): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TPST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TPST, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $11Median $11High $11

The green dot is the last close — the median target sits +1036.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Jan 2026HC Wainwright & Co.UpgradeBuy$11
22 Jan 2026HC Wainwright & Co.UpgradeBuy—
10 Apr 2025HC Wainwright & Co.DowngradeNeutral—
10 Apr 2025ScotiabankDowngradeSector Perform—
28 Mar 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025ScotiabankMaintainsSector Outperform—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2024Piper SandlerMaintainsOverweight—
10 Oct 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
21 June 2024Piper SandlerReiteratesOverweight—
20 June 2024HC Wainwright & Co.ReiteratesBuy—
13 May 2024HC Wainwright & Co.ReiteratesBuy—
10 May 2024HC Wainwright & Co.ReiteratesBuy—
20 Mar 2024HC Wainwright & Co.ReiteratesBuy—
14 Mar 2024ScotiabankInitiatesSector Outperform—
13 Mar 2024ScotiabankInitiatesSector Outperform—
12 Mar 2024HC Wainwright & Co.MaintainsBuy—
8 Feb 2024JefferiesInitiatesBuy—
11 Oct 2023HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TPST appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TPST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Tempest Therapeutics, Inc. (TPST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 77% of US stocks

Price / sales
—
Price / book
17.0×

Cheaper than 6% of US stocks

EV / EBITDA
−1.0×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−931.1%

Higher than 2% of US stocks

Return on assets
−79.4%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tempest Therapeutics, Inc. (TPST) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tempest Therapeutics, Inc. has a market value of $16.0M and an enterprise value of $22.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$40.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$20.7M.

  • Shares outstanding: 16.0M.

  • Trailing P/E: −0.2×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Tempest Therapeutics, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

TPST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TPSTTempest Therapeutics, Inc.$16.0M
37
CNSYCerenome, Inc.$15.4M
17
ICUSeastar Medical Holding Corp.$15.6M
21
LSTALisata Therapeutics, Inc.$15.3M
56
PASGPassage Bio, Inc.$15.3M
43
DAREDaré Bioscience, Inc.$15.2M
27
MBRXMoleculin Biotech, Inc.$15.1M
25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tempest Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TPST news & analysis

Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket

Benzinga · 16 Sept 2026positive

Tempest Therapeutics shares traded sharply higher in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd.

Why it matters — The option agreement with Hebei Senlang represents a new strategic partnership for Tempest that watchers of the company would want to track.

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

GlobeNewsWire · 15 Sept 2026positive

Tempest Therapeutics announced it has secured an exclusive option to license a clinical-stage CD7-targeted lentiviral in vivo CAR-T platform. This transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year.

Why it matters — A TPST watcher would care because this expands Tempest's in vivo CAR-T capabilities and deepens its pipeline in the CD7-targeted oncology space ahead of the planned clinic entry of its existing platform.

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

GlobeNewsWire · 11 Sept 2026neutral

Tempest Therapeutics announced a private placement of up to $7.5 million, consisting of $2.5 million in upfront proceeds and up to approximately $5 million in potential aggregate gross proceeds upon the full exercise of warrants.

Why it matters — TPST watchers would care because this private placement provides the company with additional capital to fund its operations, with further potential proceeds contingent on warrant exercise.

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 8 Sept 2026neutral

Tempest Therapeutics announced that Matt Angel, Ph.D. will present at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation is scheduled to take place on September 8, 2026, with Tempest describing itself as a clinical-stage biotechnology company developing in vivo CAR-T therapies for cancer and autoimmune disease.

Why it matters — A presentation at a major investment conference gives Tempest Therapeutics (TPST) an opportunity to increase visibility among investors and industry participants.

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 13 Aug 2026positive

Tempest Therapeutics reported second quarter 2026 financial results and announced a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T. First patient dosing is anticipated in the fourth quarter of 2026, with initial clinical data expected in the first half of 2027.

Why it matters — The collaboration and upcoming milestones for TPST-4003 signal progress in Tempest's pipeline toward clinical-stage development.

FAQ

Frequently asked questions about TPST stock

What is the TPST stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Tempest Therapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $11 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TPST stock a buy right now?

Of the 1 analysts covering Tempest Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tempest Therapeutics, Inc. 37 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TPST?

As at 19 Sept 2026, Tempest Therapeutics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will TPST stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1036.4% from the last close, and Ticker Nerd's factor model ranks Tempest Therapeutics, Inc. 37 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TPST stock forecast for 2030?

No analyst covering Tempest Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TPST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $11 over the next 12 months.

What does Tempest Therapeutics, Inc. do?

Tempest Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cancer therapies through targeted and immune-mediated mechanisms.

What is the latest news on TPST?

The most recent item we track (Benzinga, 16 Sept 2026): "Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket". Tempest Therapeutics shares traded sharply higher in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd.

Company

About Tempest Therapeutics, Inc.

Tempest Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cancer therapies through targeted and immune-mediated mechanisms. The company’s current pipeline centers on small molecule and cell therapy programs designed to address multiple oncology indications, including solid tumors and hematologic cancers. Its portfolio includes advanced investigational candidates that aim to modulate tumor biology, enhance anti-tumor immune responses, and broaden the reach of next-generation cell therapy approaches. Tempest Therapeutics also works with partners on certain clinical programs, reflecting a business model centered on drug development, clinical research, and translational oncology. Based in Brisbane, California, Tempest Therapeutics Inc. operates within the biopharmaceutical sector as a research-driven company advancing experimental treatments toward clinical evaluation.

CEO Dr. Matthew Angel Ph.D. · 4 employees · United States · https://www.tempesttx.com